With few significant increases in common IBD inflammation indicators like IL-1β and only No Gavage mice displaying increased IL-17 (68, 69), we observed little evidence of a systemic, uncontrolled, immune response, regardless of treatment group. The gene discussed is IL17A; the disease is inflammatory bowel disease.